Beware of deintensification of radiation therapy in patients with p16-positive oropharynx cancer and rheumatological diseases
- 1 July 2017
- journal article
- case report
- Published by Elsevier in Practical Radiation Oncology
- Vol. 7 (4) , e261-e262
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on PowderInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus–Associated Oropharyngeal Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related TumorsJournal of Clinical Oncology, 2015
- Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant MetastasisJournal of Clinical Oncology, 2013
- De-intensification of treatment for human papilloma virus associated oropharyngeal squamous cell carcinoma: A discussion of current approachesPractical Radiation Oncology, 2012
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010